USD
$0.00
(0.00%
)At Close (As of Dec 12, 2025)
$11.35M
Market Cap
-
P/E Ratio
-20.05
EPS
$18.35
52 Week High
$5.00
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$551K |
| Total Revenue | $0 |
| Cost Of Revenue | $551K |
| Costof Goods And Services Sold | $551K |
| Operating Income | -$32M |
| Selling General And Administrative | $13M |
| Research And Development | $19M |
| Operating Expenses | $31M |
| Investment Income Net | - |
| Net Interest Income | $2.5M |
| Interest Income | $2.6M |
| Interest Expense | $90K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $551K |
| Income Before Tax | -$30M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$30M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$30M |
| Ebitda | -$30M |
| Net Income | -$30M |
| Field | Value (USD) |
|---|---|
| Total Assets | $45M |
| Total Current Assets | $42M |
| Cash And Cash Equivalents At Carrying Value | $10M |
| Cash And Short Term Investments | $10M |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | $3.4M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $31M |
| Other Current Assets | $594K |
| Other Non Current Assets | - |
| Total Liabilities | $7M |
| Total Current Liabilities | $5.4M |
| Current Accounts Payable | $1.2M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $2.3M |
| Total Non Current Liabilities | $1.5M |
| Capital Lease Obligations | $3.8M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $3.8M |
| Other Current Liabilities | $1.9M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $38M |
| Treasury Stock | - |
| Retained Earnings | -$262M |
| Common Stock | $3K |
| Common Stock Shares Outstanding | $25M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$551K |
| Total Revenue | $0 |
| Cost Of Revenue | $551K |
| Costof Goods And Services Sold | $551K |
| Operating Income | -$32M |
| Selling General And Administrative | $13M |
| Research And Development | $19M |
| Operating Expenses | $31M |
| Investment Income Net | - |
| Net Interest Income | $2.5M |
| Interest Income | $2.6M |
| Interest Expense | $90K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $551K |
| Income Before Tax | -$30M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$30M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$30M |
| Ebitda | -$30M |
| Net Income | -$30M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Sensei Biotherapeutics, Inc. is a clinical-stage immunotherapy company headquartered in Rockville, Maryland, dedicated to developing groundbreaking therapies targeting cancer through innovative approaches that leverage the body's immune system. The company boasts a promising pipeline of novel treatments aimed at effectively engaging the immune response to eradicate tumors. With a strategic focus on advancing biotechnology and enhancing patient care, Sensei is well-positioned to contribute substantially to the transformative landscape of cancer therapeutics, catering to an increasing demand for effective and targeted treatment options in oncology.